Kymriah (tisagenlecleucel-T) / University of Pennsylvania, Novartis - LARVOL DELTA

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update (ASH 2025) - P2 | "After a median follow-up of >5 years, tisagenlecleucel continues to demonstrate durableresponses and prolonged survival in pts with r/r FL including in pts with high-risk disease characteristics.No new safety signals were reported. More than 75% of patients were alive, and approximately halfremained progression-free at this final analysis, indicating the curative potential of tisagenlecleucel in r/rFL."

Clinical • Clinical data • P2 data • Acute Myelogenous Leukemia • Basal Cell Carcinoma • Bladder Cancer • Bowens Disease • Follicular Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Melanoma • Myelodysplastic Syndrome • Neutropenia • Non-melanoma Skin Cancer • Pneumonia • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Thrombocytopenia • Urothelial Cancer

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry (ASH 2025) - P | "At the timeof CAR T-cell infusion, 109/195 (56%) patients were in complete (CR) or partial response (PR), and 84 (43%)had stable (SD) or progressive disease (PD) (missing data: 1%).One hundred thirty-eight (71%) patients received axi-cel, 26 (13%) tisa-cel, and 31 (16%) liso-cel. Efficacy and toxicity data, particularlywith respect to neurotoxicity, were consistent with those observed in systemic DLBCL. Further studies areneeded to support these results over the long term and to determine the optimal place of CAR T-cellswithin the therapeutic options of CNS lymphomas."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Antigen Escape in Relapsed/Refractory Large B-Cell Lymphoma: A Case Series of CD20 Expression Loss After CD20-Directed Therapy (SOHO 2026) - "Context: CD20-directed therapy remains foundational in the management of LBCL, yet relapsed disease may emerge with loss of CD20 expression, limiting the utility of rituximab- or obinutuzumab-based regimens or bispecific antibodies...All patients had received prior CD20-directed therapy, most commonly rituximab-containing regimens, including R-CHOP, REPOCH, R-GemOx, R-ICE, rituximab-lenalidomide, or bendamustine-rituximab. Several also received contemporary salvage approaches, including polatuzumab-based therapy, epcoritamab, tafasitamab-lenalidomide, radiation, lymphodepleting chemotherapy, and CAR-T therapy with axicabtagene ciloleucel or tisagenlecleucel... CD20-negative conversion is a clinically consequential pattern of relapse in heavily pretreated LBCL. This series highlights the importance of repeat biopsy at progression to reassess targetable antigen expression and avoid ineffective recycling of CD20-directed therapy. Antigen reassessment should inform..."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD22

Transient suppression of fibrinolytic potential during cytokine release syndrome after chimeric antigen receptor T-cell therapy in B-cell malignancies. (PubMed, Thromb Res) - "CRS after CAR T-cell therapy is associated with transient suppression of fibrinolytic potential during sustained coagulation activation. Suppressed fibrinolytic potential was associated with elevated sIL-2R levels, suggesting a link between immune activation and haemostatic dysregulation during CRS. T/P-GA may provide functional insights beyond conventional haemostatic markers."

Journal • Hematological Malignancies • Inflammation • Oncology • IL2

Radiation Therapy for Bridging to CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma - A Multicenter Analysis by the GoCART Coalition and the EBMT Lymphoma Working Party (ASTRO 2026) - "Eligible for this analysis were adult patients with LBCL who received RT (± corticosteroids) for bridging prior to axicabtagene ciloleucel (axi-cel) or tisagen lecleucel (tisa-cel) between 2018 and July 2023. In this large multicenter analysis, RT used for bridging to CART resulted in considerable response rates and durable remissions after CART. Details of RT and patient characteristics will be presented."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Hepatobiliary Adverse Event Signals Across FDA-Approved CAR-T Cell Therapy Agents: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (ACG 2026) - "Six agents were analyzed: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel, by both generic and proprietary names from respective FDA approval dates. Of 22,486 CAR-T-related adverse event reports, 466 (2.1%) involved hepatobiliary adverse events; all met seriousness criteria (100%), with overall CFR 36.7% (171/466). Tisagenlecleucel had a positive signal (ROR 2.45; 95% CI 2.01-2.97; PRR 2.39; chi-square 69.53; CFR 51.3%), exceeding ciltacabtagene autoleucel (ROR 0.33; Z=10.60, p< 0.001) and brexucabtagene autoleucel (ROR 0.79; Z=5.49, p< 0.001). CD19-targeted agents showed higher disproportionality than BCMA-targeted agents (ROR 2.26; 1.75-2.91; p< 0.001)."

Adverse events • CAR T-Cell Therapy • Hematological Malignancies • Hepatology • Liver Failure

Host immune biomarkers associated with infection risk after CAR T-cell therapy. (PubMed, J Infect) - "Longitudinal immune profiling identified distinct immunological signatures linked to infection risk and CAR-T-related toxicities. These findings suggest a role for immune monitoring in improving risk stratification and guiding supportive care after CAR-T therapy."

Biomarker • IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A • RNASE1 • TNFA

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study. (PubMed, Blood) - P2 | "We evaluated the combination of time-limited ibrutinib and CTL019 CAR-T in 20 patients with MCL on the phase II TARMAC study. Overall, the safety and efficacy of the combination of BTKi and T-cell redirecting immunotherapy appears promising and merits further exploration. ClinicalTrials.gov NCT04234061."

CAR T-Cell Therapy • IO biomarker • Journal • P2 data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • TP53

Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. (PubMed, Blood Neoplasia) - P1 | "Altogether, these findings suggest administering ibrutinib before leukapheresis may modify T-cell characteristics in the collected material, thereby improving final CAR T-cell product quality and clinical outcomes for patients with R/R LBLC treated with tisagenlecleucel. This trial was registered at www.clinicaltrials.gov as #NCT03876028."

Clinical • Journal • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IFNG • IL2

Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells. (PubMed, Blood Adv) - "We analyzed large B-cell lymphoma patients in the DESCAR-T registry treated with axi-cel or tisa-cel in ≥3rd line (L3+) and TAFA-LEN before (n=15, 'TL-pre-CAR-T' set) or directly after (n=52, 'TL-post-CAR-T' set) CAR T-cell. The bORR, bCRR, 6-month PFS and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1% and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatments improved outcomes of patients who relapsed after CAR T-cell."

CAR T-Cell Therapy • Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia. (PubMed, Blood) - "CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD27 • CD4 • CD8 • KLRG1

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: results from the phase Ib PORTIA study. (PubMed, Blood Adv) - P1 | "Emerging efficacy with tisagenlecleucel was observed when pembrolizumab was given the day before tisagenlecleucel; however, the limited patient sample and short follow-up do not allow for definitive conclusions. Adding pembrolizumab to tisagenlecleucel did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion if given the day before tisagenlecleucel (NCT03630159)."

IO biomarker • Journal • P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SOHO 2026) - " This retrospective, US and EU physician-abstracted medical chart review study collected data for adults with R/R DLBCL who received tafasitamab (±lenalidomide) and subsequent CAR-T in second-line (2L), 3L, or 4L...CAR-T therapies administered were axicabtagene ciloleucel (65.1%), followed by lisocabtagene maraleucel (21.9%) and tisagenlecleucel (13.0%)... This large, real-world study indicates that prior exposure to tafasitamab does not appear to compromise the effectiveness or safety of subsequent CAR-T therapy in patients with R/R DLBCL. These real-world study findings support the sequencing strategy of tafasitamab followed by CAR-T. Funding: This study was funded by Incyte Corporation."

CAR T-Cell Therapy • Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Comparative Efficacy and Safety of Approved Therapies in ≥3L Relapsed/Refractory Large B-Cell Lymphoma: A Bayesian Network Meta-Analysis (SOHO 2026) - "Background: Multiple novel agents are approved for ≥3L relapsed/refractory large B-cell lymphoma, including chimeric antigen receptor T-cell (CAR-T) products (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisacel]), bispecific antibodies (epcoritamab, glofitamab, mosunetuzumab), antibody-drug conjugates (polatuzumab vedotin + bendamustine, rituximab [pola-BR], loncastuximab tesirine), and others (tafasitamab + lenalidomide, selinexor). CAR-T therapies ranked highest for CR rate but with greater toxicity and selection bias. Among bispecific antibodies, epcoritamab ranked among the most favorable for combined efficacy and safety (SUCRA, 58.3% vs 56.1% for glofitamab and 47.8% for mosunetuzumab). Given the near-disconnected, star-topology network and predominantly single-arm data, results carry very low certainty per CINeMA and should be interpreted cautiously."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study (ASH 2022) - "Ibrutinib (560mg daily) was commenced at least 7 days prior to leukapheresis and continued throughout optional bridging, lymphodepletion (fludarabine 25mg/m2 and cyclophosphamide 250mg/m2 each daily x 3) and for 6 months after tisa-cel infusion...4 pts required bridging: venetoclax (n=1) or chemotherapy (n=3)... This time-limited combination of ibrutinib and tisa-cel is a highly effective treatment in RR-MCL leading to a high rate of durable responses, irrespective of prior BTKi exposure and/or TP53 status. Deep responses were correlated with more robust CAR-T expansion and a less exhausted baseline T-cell state. The safety profile was favourable."

Clinical • IO biomarker • Atrial Fibrillation • Cardiovascular • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation • CD8 • PD-1 • TP53

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. (PubMed, Blood) - P2 | "Patients in part 1 received once-daily itacitinib 200 mg 3 days before IEC therapy (axicabtagene ciloleucel [axi-cel], brexucabtagene autoleucel, or tisagenlecleucel) through Day 26, with guidelines for use of other CRS/ICANS interventions. Importantly, itacitinib did not impact IEC therapy efficacy (objective response rate at 6 months: 39.1% for itacitinib 200 mg bid vs 26.1% for placebo). Trial registration: clinicaltrials.gov; #NCT04071366."

Journal • P2 data • Hematological Disorders • Hematological Malignancies • Oncology

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma (ASH 2021) - P2 | "CD19 CAR products included axicabtagene (23 pts; 74%), tisagenlecleucel (4 pts; 13%) and brexucabtagene (4 pts; 13%). Early use of IL-1 receptor inhibitor anakinra appears to be safe and feasible, and reduces the rates of both severe CRS and ICANS with the comparable response rates in adult pts with R/R B-cell lymphoma receiving CD19 CAR T cells. The overall severe CRS and ICANS rates were 6% each with relatively low utilization of tocilizumab (29%) and corticosteroids (19%). In pts receiving axicabtagene, the rate of severe ICANS was 4%."

CAR T-Cell Therapy • Clinical • P2 data • Critical care • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Corticosteroids With or Without Interleukin 6-Directed Therapy for the Management of Immune Effector Cell–Associated Neurotoxicity Syndrome: A Meta-Analysis (SOHO 2026) - " A systematic search of PubMed, ClinicalTrials.gov, and conference proceedings (2017–2025) was performed using the terms ICANS, CAR-T, IL-6, corticosteroid, tocilizumab, siltuximab, anakinra, axicabtagene, tisagenlecleucel, and lisocabtagene. The combination of corticosteroids with tocilizumab does not significantly improve ICANS rates or severity over either strategy. Costimulatory domains remain one of the strongest predictors of ICANS toxicity. Randomized, product-stratified trials are urgently needed to define optimal ICANS-prevention protocols."

Retrospective data • Oncology • IL6 • TNFA

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update (ASH 2022) - P1 | "CRS was managed with tocilizumab, corticosteroids, and vasopressors in 7 (70%), 3 (30%), and 1 (10%) pts at DL2, respectively, and 1 DL3 pt (50%) received tocilizumab...ICANS management was based on dexamethasone, methylprednisolone, and anakinra in 2 (67%), 1 (33%), and 1 (33%) pts at DL2, respectively, and 1 DL4 pt (50%) received dexamethasone...At a 25-fold lower dose, rapcabtagene autoleucel expansion at DL2 was comparable by qPCR to tisagenlecleucel expansion in JULIET... Rapcabtagene autoleucel is a potent new CD19-directed CAR-T cell tx with distinct cellular kinetics, durable efficacy, and a manageable safety profile. DL2 (12.5×106) CAR+ viable T cells is the recommended dose for Phase III studies, based on the CR rate, favorable safety profile, and cellular kinetics. Updated results with expanded cellular kinetics and biomarker analyses will be presented at the meeting."

Clinical • IO biomarker • P1 data • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

FOURTH GENERATION HUCART19-IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI-CD19 CAR T-CELL THERAPY (ICML 2023) - "The median age is 65 years (53–74), 77% male, 92% had prior anti-CD19 CART (axi-cel 6, tisa-cel 4, brex-cel 1, tisa-cel+liso-cel 1) with 67% relapsed and 33% refractory to prior CART...CRS was seen in 7 (58%) pts (G1 in 4, G2 in 2, G3 in 1) and ICANS in 2 (17%) pts (G1 in 1, G2 in 2), which were transient/reversible with 3 (25%) pts requiring tocilizumab... HuCART19-IL18 therapy results in durable responses in pts with CD19+ NHL who are R/R to prior 2nd generation anti-CD19 CART. Enrollment continues at DL4 with protocol amendment to include CD19+ B-ALL pts."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL18

Real-World Outcomes of CD19 CAR T-Cell Therapies in Follicular Lymphoma: A Comparative Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel (SOHO 2026) - "Safety outcomes included CRS or pyrexia within 30 days, ICANS, infections, neutropenia, and tocilizumab requirement. In this large real-world analysis of FL patients treated with CD19 CAR T-cell therapy, all three products demonstrated durable survival with toxicity profiles consistent with prior clinical trial experience. Differences in CRS, neurotoxicity, and supportivecare requirements highlight the importance of individualized product selection and post–CAR T-cell therapy monitoring. These findings provide important real-world context to inform clinical decisionmaking, and further highlight the need for prospective studies with longer follow-up."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Nonresponder CAR-T Infusion Products (SOHO 2026) - "Design: We analyzed single-cell RNA-seq data from CAR-T infusion products of 24 patients with DLBCL (12 responders [R], 8 NR, 4 partial responders; 18 axicabtagene ciloleucel, 6 tisagenlecleucel) from GSE197268. NR CAR-T products for DLBCL carry compositionally altered ribosomes alongside active ISR signaling, uncoupling ribosome biogenesis from effector translation. This translational stalling axis is distinct from exhaustion or metabolic dysfunction and positions ISR as a therapeutic intervention point for improving CAR-T efficacy in aggressive B-cell lymphomas. ATF4: activating transcription factor 4, BAX: BCL2-associated X protein, CAR: chimeric antigen receptor, CAR-T: chimeric antigen receptor T-cell, CDKN1A: cyclin-dependent kinase inhibitor 1A, DDIT3: DNA damage-inducible transcript 3 (also known as CHOP), FAS: Fas cell surface death receptor, GADD45A: growth arrest and DNA damage-inducible 45 alpha, GEO: Gene Expression Omnibus, MDM2: mouse double minute 2..."

CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ATF4 • BAX • CDKN1A • DDIT3 • FAS • MDM2 • RPL11 • RPL22 • RPL23 • RPL5 • TCF4

Prior Bendamustine Exposure Within 12 Months and Outcomes After CAR-T or Bispecific Antibody Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Real-World Analysis (SOHO 2026) - "Patients/Participants: Adults aged 18 years or older with DLBCL (ICD-10 C83.3) receiving axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, epcoritamab, or glofitamab between 2018 and 2025. Prior bendamustine within 12 months was directionally associated with higher 6-month mortality in this propensity-matched real-world cohort, consistent with the T-cell fitness hypothesis. However, no outcome was statistically significant, and the signal attenuated at 12 months, suggesting dilution by bispecific antibody recipients or limited follow-up capture. Larger prospective analyses are needed to define optimal washout intervals before T-cell-dependent immunotherapy."

Bispecific • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Real-World Incidence and Management of Cytokine Release Syndrome Following CAR-T Therapy in B-Cell Lymphoma: A Systematic Review (SOHO 2026) - "New agents such as anakinra (IL-1 inhibitor) and cilgavimab/tixagevimab (for infection-related CRS) are emerging, with tocilizumab and corticosteroids still being the cornerstones. CRS is a relatively small but serious adverse reaction of CAR-T therapy. Early intervention, standardized grading, and emerging therapies (eg, anakinra, prophylaxis) improve safety. Additional prospective studies are required to further optimize protocols and minimize morbidity."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Review • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2 (ASH 2023) - P2 | "Rates of severe (≥ grade 3) ICANS remain high with axicabtagene (axi-cel) and brexucabtagene (brexu-cel) at > 30%...The median age of the cohort was 65yrs (range: 24 – 81yrs) and patients received axi-cel (19 pts; 63%), brexu-cel (5 pts; 17%), lisocabtagene (4 pts; 13%) and tisagenlecleucel (2 pts; 7%)...23 patients (77%) received tocilizumab and 18 (60%) received steroids for CRS and/or ICANS... Early use of prophylactic anakinra was safe, feasible and reduced the rate of severe ICANS without affecting efficacy in adult patients receiving anti-CD19 CAR-T for r/r B-cell lymphoma. Rates of severe ICANS were very similar between cohorts 1 and 2; at 9.7% and 10% in the entire cohorts, respectively, and 11% and 12.5% in patients treated with CD28-containing CARs, respectively. The risk-adapted dosing of anakinra likely contributed to the low rates of severe ICANS in this study."

CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • B Cell Lymphoma • CNS Disorders • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology